104亿欧元!赛默飞世尔收购QIAGEN

2020-03-04 佚名 生物探索

赛默飞世尔以104亿欧元(约115.9亿美元),即每股39欧元现金收购QIAGEN。

3月3日,全球科学服务的领导者赛默飞世尔科技联合全球领先分子诊断和样品制备技术提供商的QIAGEN宣布,双方董事会已一致通过,赛默飞以104亿欧元(约115.9亿美元),即每股39欧元现金收购QIAGEN的提议。该交易预计将于2021年上半年完成。

据报道,早在2019年11月,赛默飞就计划收购QIAGEN,这一消息使得QIAGEN的股价节节攀升。对此,摩根大通(JP Morgan)也上调了QIAGEN的股票评级,从减持(Underweight)上调为增持(Overweight)。然而当时收购并未成功,Qiagen宣布其董事会已经完成了所有收购要约的战略审查,并决定目前不出售是公司最好的选择。消息公布后,Qiagen股票即下跌27.5%。

对于此次收购,赛默飞董事长、总裁兼首席执行官Marc N. Casper表示:“我们很高兴能够产品组合进一步补充,以推进客户从发现到诊断的重要工作。此次收购有望利用我们行业领先的能力和研发专业知识来加速创新并满足新兴医疗需求。”

QIAGEN临时首席执行官兼分子诊断业务领域主管高级副总裁Thierry Bernard说道:“QIAGEN的愿景一直是通过我们独特的Sample to Insight分子测试解决方案来改善生活。而与赛默飞的战略合作将使我们进入一个充满希望的新时代,并为我们的员工提供机会发挥更大的价值。此次合并使我们能够加快解决方案的扩展,为全球客户提供突破性的突破,从而增强我们对生命科学的认识并改善健康状况。”

Marc N. Casper总结说:“我们期待并欢迎QIAGEN的员工加入赛默飞,为通过新的分子诊断技术和改进的生命科学工作流程而推动精密医学发展的新机遇感到高兴。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2027897, encodeId=53fa202e897f3, content=<a href='/topic/show?id=5a461495569' target=_blank style='color:#2F92EE;'>#QIAGEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14955, encryptionId=5a461495569, topicName=QIAGEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sat Nov 14 04:37:00 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465305, encodeId=8bac1465305f7, content=<a href='/topic/show?id=a74a926224b' target=_blank style='color:#2F92EE;'>#赛默飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92622, encryptionId=a74a926224b, topicName=赛默飞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12366697882, createdName=yangwen5711, createdTime=Fri Mar 06 10:37:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086101, encodeId=e81a20861019c, content=<a href='/topic/show?id=ea5e9262303' target=_blank style='color:#2F92EE;'>#赛默飞世尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92623, encryptionId=ea5e9262303, topicName=赛默飞世尔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Tue Aug 25 09:37:00 CST 2020, time=2020-08-25, status=1, ipAttribution=)]
    2020-11-14 luwei00
  2. [GetPortalCommentsPageByObjectIdResponse(id=2027897, encodeId=53fa202e897f3, content=<a href='/topic/show?id=5a461495569' target=_blank style='color:#2F92EE;'>#QIAGEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14955, encryptionId=5a461495569, topicName=QIAGEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sat Nov 14 04:37:00 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465305, encodeId=8bac1465305f7, content=<a href='/topic/show?id=a74a926224b' target=_blank style='color:#2F92EE;'>#赛默飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92622, encryptionId=a74a926224b, topicName=赛默飞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12366697882, createdName=yangwen5711, createdTime=Fri Mar 06 10:37:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086101, encodeId=e81a20861019c, content=<a href='/topic/show?id=ea5e9262303' target=_blank style='color:#2F92EE;'>#赛默飞世尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92623, encryptionId=ea5e9262303, topicName=赛默飞世尔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Tue Aug 25 09:37:00 CST 2020, time=2020-08-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2027897, encodeId=53fa202e897f3, content=<a href='/topic/show?id=5a461495569' target=_blank style='color:#2F92EE;'>#QIAGEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14955, encryptionId=5a461495569, topicName=QIAGEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sat Nov 14 04:37:00 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465305, encodeId=8bac1465305f7, content=<a href='/topic/show?id=a74a926224b' target=_blank style='color:#2F92EE;'>#赛默飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92622, encryptionId=a74a926224b, topicName=赛默飞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12366697882, createdName=yangwen5711, createdTime=Fri Mar 06 10:37:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086101, encodeId=e81a20861019c, content=<a href='/topic/show?id=ea5e9262303' target=_blank style='color:#2F92EE;'>#赛默飞世尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92623, encryptionId=ea5e9262303, topicName=赛默飞世尔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Tue Aug 25 09:37:00 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

相关资讯

赛默飞进博会全球首发三款新品,助力本土行业创新升级

11月5-10日,赛默飞携逾40款展品亮相第二届进博会,通过五大展区集中展示其在学术科研、医疗健康与精准医疗、生物制品与制药、食品安全及环境监测等重点垂直领域的最新数字化解决方案和创新成果。

全球规模很大CDMO赛默飞临床试验(苏州)工厂扩建已完成

扩大投资,助力临床客户加速药物上市;携手合作,推动药物研发惠及广大患者。